International Society of Liquid Biopsy shared an article by Luís F Leite da Silva, et al. on X:
“Plasma ctDNA Kinetics Predicts Therapy Response in Advanced NSCLC.
Key Findings from a Systematic Review & Meta-Analysis:
- ctDNA clearance/decrease strongly correlates with improved PFS & OS in NSCLC patients.
- HR for PFS: 0.32 (68% lower risk of progression with ctDNA clearance).
- HR for OS: 0.31 (69% lower risk of death with ctDNA reduction).
- Benefits seen across targeted therapy (TT) & immune checkpoint blockade (ICB).
- Tumor-informed assays showed a stronger predictive value vs. tumor-agnostic assays.
Longitudinal ctDNA monitoring can revolutionize personalized NSCLC treatment decisions!
Read more.”
Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis.
Authors: Luís F Leite da Silva, et al.
